Founded in 2019, SeaBeLife is a biotech startup developing drug candidates to block cell necrosis. Today, it’s announced a funding boost of almost €1.4 million financing from Bpifrance. SeaBeLife specialises in the development of drug candidates that block cellular necrosis in order to protect or regenerate organs affected by severe pathologies – for which there…
This content is for members only. Visit the site and log in/register to read.
The post Brittany-based biotech startup SeaBeLife picks up €1.4 million appeared first on EU-Startups.
